Please Wait.....

Report

Global Insulin Market for Type 1 and Type 2 Diabetes

Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research

The global insulin market for type 1 and type 2 diabetes is expected to reach USD 25.70 billion by 2032 from USD 19.06 billion in 2024, growing at a substantial CAGR of 3.9% in the forecast period of 2025 to 2032.

Market Segmentation:
Global Insulin Market for Type 1 And Type 2 Diabetes Segmentation, Type (Type 2 Diabetes and Type 1 Diabetes), Product Type (Long Acting Insulin, Rapid-Acting Insulin, Short Acting Insulin, and Others), Absorption Site (Basal, Bolus, and Others), Age Group (Adult Patients, Geriatric Patients, and Pediatric Patients), Source (Analog Insulin, Human Insulin, and Others), Delivery Method (Insulin Pens, Vial & Syringe, Insulin Pumps, Inhalable Insulin, and Implantable Insulin Delivery Systems), Gender (Male and Female), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Diabetes Clinics & Specialty Pharmacies), By Countries (U.S., Canada, Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Philippines, New Zealand, Taiwan, Vietnam, Rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Denmark, Norway, Poland, Rest of Europe, Brazil, Argentina, Chile, Peru, Rest of South America, South Africa, U.A.E., Egypt, Saudi Arabia, Israel, Kuwait, and Rest of Middle East and Africa)- Industry Trends and Forecast to 2032

Overview of Global Insulin Market for Type 1 and Type 2 Diabetes Dynamics:

Driver

- Rising prevalence of diabetes
Restraint

- Adverse effects of high dosage of insulin

Opportunity

- Advancements in insulin formulation and delivery technologies
Market Players:

The key market players operating in the global insulin market for type 1 and type 2 diabetes are listed below:

- Novo Nordisk A/S (Denmark)
- Eli Lilly and Company (U.S.)
- Sanofi (France)
- Biocon (India)
- Lupin (India)
- Shanghai Fosun Wanbang (Jiangsu)
- Pharmaceutical Group Co., Ltd. (China)
- Diasome Pharmaceuticals, Inc. (U.S.)
- SciGen Pte. Ltd. (Singapore)
- Wockhardt (India)
- MJ Biopharma Pvt. Ltd. (India)
- Oramed Pharmaceuticals (U.S.)
- Adocia (France)
- Nektar Therapeutics (U.S.)

TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 14
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 16
2 MARKET SEGMENTATION 19
2.1 MARKETS COVERED 19
2.2 GEOGRAPHICAL SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 25
2.7 TYPE LIFELINE CURVE 25
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.9 DBMR MARKET POSITION GRID 27
2.10 SECONDARY SOURCES 29
2.11 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 35
4.1 PESTAL ANALYSIS 38
4.2 PORTERS FIVE FORCES ANALYSIS 39
4.3 EPIDEMIOLOGY 40
4.4 INDUSTRY INSIGHTS 45
4.5 KEY MARKETING STRATEGIES FOR THE GLOBAL ORAL INSULIN MARKET (TYPE 1 & TYPE 2 DIABETES) 51
4.6 MERGERS AND ACQUISITION 53
4.7 PIPELINE ANLYSIS 54
5 REGULATORY 56
5.1 REGULATORY FRAMEWORK FOR THE ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 56
5.1.1 REGULATORY APPROVAL PROCESS 56
5.1.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 57
5.1.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 57
5.1.4 LICENSING AND REGISTRATION 57
5.1.5 POST-MARKETING SURVEILLANCE 58
5.1.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 58
5.2 REGULATORY FRAMEWORK FOR THE NORTH AMERICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 59
5.2.1 REGULATORY APPROVAL PROCESS 59
5.2.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 60
5.2.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 60
5.2.4 LICENSING AND REGISTRATION 60
5.2.5 POST-MARKETING SURVEILLANCE 60
5.2.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 61
5.3 REGULATORY FRAMEWORK FOR THE SOUTH AMERICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 62
5.3.1 REGULATORY APPROVAL PROCESS 62
5.3.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 62
5.3.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 63
5.3.4 LICENSING AND REGISTRATION 64
5.3.5 POST-MARKETING SURVEILLANCE 64
5.3.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 64
5.4 REGULATORY FRAMEWORK FOR THE EUROPE ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 65
5.4.1 REGULATORY APPROVAL PROCESS 65
5.4.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 65
5.4.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 66
5.4.4 LICENSING AND REGISTRATION 67
5.4.5 POST-MARKETING SURVEILLANCE 67
5.4.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 67
5.5 REGULATORY FRAMEWORK FOR THE MIDDLE EAST & AFRICA (MEA) ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 68
5.5.1 REGULATORY APPROVAL PROCESS 68
5.5.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 68
5.5.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 69
5.5.4 LICENSING AND REGISTRATION 70
5.5.5 POST-MARKETING SURVEILLANCE 70
5.5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 71
6 MARKET OVERVIEW 76
6.1 DRIVERS 78
6.1.1 GROWING INCIDENCE OF DIABETES WORLDWIDE 78
6.1.2 GROWING GERIATRIC POPULATION ENCOURAGING DEMAND FOR NON-INVASIVE DIABETES SOLUTIONS 79
6.1.3 ADVANCEMENTS IN ORAL INSULIN FORMULATIONS 80
6.1.4 ENHANCED PATIENT COMPLIANCE AND CONVENIENCE WITH ORAL INSULIN 81
6.2 RESTRAINTS 82
6.2.1 ADVERSE EFFECTS OF HIGH DOSAGE OF INSULIN 82
6.2.2 HIGH PRODUCTION AND DEVELOPMENT COSTS ASSOCIATED WITH INSULIN 82
6.3 OPPORTUNITIES 84
6.3.1 ADVANCEMENTS IN ORAL INSULIN DELIVERY TECHNOLOGIES 84
6.3.2 REVOLUTIONIZING DIABETES MANAGEMENT WITH NEEDLE-FREE ORAL INSULIN 85
6.3.3 INCREASING PHARMACEUTICAL INVESTMENTS AND STRATEGIC COLLABORATIONS 86
6.4 CHALLENGES 87
6.4.1 INSULIN ACCESSIBILITY CHALLENGES IN RURAL AND UNDERSERVED REGIONS 87
6.4.2 LIMITED SHELF LIFE ASSOCIATED WITH ORAL INSULIN 87
7 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY TYPE 89
7.1 OVERVIEW 90
7.2 TYPE 2 DIABETES 93
7.3 TYPE 1 DIABETES 93
8 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY TECHNOLOGY 94
8.1 OVERVIEW 95
8.2 POLYMERIC NANOPARTICLES 98
8.3 NANOPARTICLE-BASED DELIVERY SYSTEMS 98
8.4 ENCAPSULATION TECHNOLOGY 99
8.5 LIPID-BASED NANOCARRIERS 99
9 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY PRODUCT TYPE 100
9.1 OVERVIEW 101
9.2 CAPSULES 104
10 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY ABSORPTION SITE 105
10.1 OVERVIEW 106
10.2 INTESTINAL 109
11 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY FORMULATION TYPE 110
11.1 OVERVIEW 111
11.2 ENTERIC-COATED ORAL INSULIN 114
12 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY AGE GROUP 115
12.1 OVERVIEW 116
12.2 ADULT PATIENTS 119
12.3 GERIATRIC PATIENTS 119
12.4 PEDIATRIC PATIENTS 120
13 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY GENDER 121
13.1 OVERVIEW 122
13.2 MALE 125
13.3 FEMALE 125
14 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY DISTRIBUTION CHANNEL 126
14.1 OVERVIEW 127
14.2 RETAIL PHARMACIES 130
14.3 HOSPITAL PHARMACIES 130
14.4 ONLINE PHARMACIES 131
14.5 DIABETES CLINICS & SPECIALTY PHARMACIES 131
15 GLOBAL ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION 132
15.1 OVERVIEW 132
15.2 NORTH AMERICA 136
15.2.1 U.S. 136
15.2.2 CANADA 136
15.2.3 MEXICO 136
15.3 EUROPE 137
15.3.1 GERMANY 137
15.3.2 FRANCE 137
15.3.3 U.K. 137
15.3.4 ITALY 137
15.3.5 RUSSIA 137
15.3.6 SPAIN 137
15.3.7 TURKEY 137
15.3.8 NETHERLAND 137
15.3.9 SWITZERLAND 137
15.3.10 AUSTRIA 137
15.3.11 IRELAND 138
15.3.12 NORWAY 138
15.3.13 POLAND 138
15.4 ASIA-PACIFIC 139
15.4.1 CHINA 139
15.4.2 INDIA 139
15.4.3 JAPAN 139
15.4.4 SOUTH KOREA 139
15.4.5 AUSTRALIA 139
15.4.6 INDONESIA 139
15.4.7 THAILAND 139
15.4.8 MALAYSIA 139
15.4.9 VIETNAM 139
15.4.10 PHILIPPINES 139
15.4.11 TAIWAN 140
15.4.12 SINGAPORE 140
15.5 SOUTH AMERICA 141
15.5.1 BRAZIL 141
15.5.2 ARGENTINA 141
15.6 MIDDLE EAST AND AFRICA 142
15.6.1 SAUDI ARABIA 142
16 COMPANY PROFILE 143
16.1 APHIOS CORPORATION 143
16.1.1 COMPANY SNAPSHOT 143
16.1.2 PIPELINE PORTFOLIO 143
16.1.3 RECENT UPDATES 143
16.2 BIOCON 144
16.2.1 COMPANY SNAPSHOT 144
16.2.2 REVENUE ANALYSIS 144
16.2.3 PIPELINE PRODUCT PORTFOLIO 145
16.2.4 RECENT DEVELOPMENT 145
16.3 DIABETOLOGY LTD 146
16.3.1 COMPANY SNAPSHOT 146
16.3.2 PIPELINE PORTFOLIO 146
16.3.3 RECENT UPDATES 146
16.4 ENDO AXIOM 147
16.4.1 COMPANY SNAPSHOT 147
16.4.2 PIPELINE PORTFOLIO 147
16.4.3 RECENT DEVELOPMENTS 147
16.5 MURLI KRISHNA PHARMA 148
16.5.1 COMPANY SNAPSHOT 148
16.5.2 PIPELINE PORTFOLIO 148
16.5.3 RECENT UPDATES 148
16.6 NIEDLFREE 149
16.6.1 COMPANY SNAPSHOT 149
16.6.2 PIPELINE PORTFOLIO 149
16.6.3 RECENT UPDATES 149
16.7 ORAMED 150
16.7.1 COMPANY SNAPSHOT 150
16.7.2 REVENUE ANALYSIS 150
16.7.3 PIPELINE PRODUCT PORTFOLIO 151
16.7.4 RECENT DEVELOPMENT 151
16.8 TRANSGENE BIOTEK LIMITED 152
16.8.1 COMPANY SNAPSHOT 152
16.8.2 REVENUE ANALYSIS 152
16.8.3 PIPELINE PORTFOLIO 153
16.8.4 RECENT DEVELOPMENT 153
17 QUESTIONNAIRE 154
18 RELATED REPORTS 157
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.